GenMark Diagnostics, Inc. (Nasdaq:GNMK) today reported financial results for the third quarter ended September 30, 2011.
Revenues for the three months ended September 30, 2011 were $1.3 million compared with $684,000 during the third quarter of 2010. The 90% year-over-year increase in total revenue reflects an increase in the number of systems in the field, growth in the Company’s test menu and a significant increase in the number of tests sold. Reagent revenues for the third quarter grew 83% year over year to $1.2 million from $656,000, while instrument and other revenues increased $82,000 due mainly to higher partnering contract revenue. The Company placed net 22 analyzers during the quarter, bringing the installed base to 141.
The gross margin was a loss of $469,000 for the three months ended September 30, 2011 compared with a loss of $439,000 for the same period in 2010. The gross loss during the third quarter of 2011 was largely driven by a charge of $421,000 against inventory, the impact of which was $0.02 per share. The inventory charge reflects the write-off of several assay production lots that did not meet the Company’s quality standards and other manufacturing inefficiencies arising from the Company’s transfer of manufacturing operations from Pasadena to Carlsbad during the second quarter of 2011. The Company believes that these charges are non-recurring since the manufacturing issues were confined to and corrected during the quarter.
Operating expenses increased $1.1 million to $5.6 million during the third quarter of 2011 compared with the third quarter of 2010. The increase in operating expenses was due primarily to higher consulting costs, increased headcount and additional spend in research and development. Research and development expenses were higher due to increased clinical trial costs and spending for new product development, specifically the Company’s Hepatitis C Virus genotyping (HCVg) and Respiratory Viral Panel tests. The Company released its HCVg test for research use only during the third quarter of 2011.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV